[go: up one dir, main page]

BR0315178A - Erythropoietin: remodeling and glycoconjugation of erythropoietin - Google Patents

Erythropoietin: remodeling and glycoconjugation of erythropoietin

Info

Publication number
BR0315178A
BR0315178A BR0315178-6A BR0315178A BR0315178A BR 0315178 A BR0315178 A BR 0315178A BR 0315178 A BR0315178 A BR 0315178A BR 0315178 A BR0315178 A BR 0315178A
Authority
BR
Brazil
Prior art keywords
erythropoietin
remodeling
glycoconjugation
peptide
deleting
Prior art date
Application number
BR0315178-6A
Other languages
Portuguese (pt)
Inventor
Shawn Defrees
David Zopf
Robert Bayer
David Hakes
Caryn Bowe
Xi Chen
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/032263 external-priority patent/WO2003031464A2/en
Priority claimed from US10/410,945 external-priority patent/US7214660B2/en
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of BR0315178A publication Critical patent/BR0315178A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"ERITROPOIETINA: REMODELAGEM E GLICOCONJUGAçãO DE ERITROPOIETINA". A invenção inclui métodos e composições para a remodelagem uma molécula de peptídeo, que inclui a adição ou deleção de um ou mais grupos glicosil a um peptídeo, e/ou a adição de um grupo de modificação ao peptídeo."Erythropoietin: remodeling and glycoconjugation of erythropoietin". The invention includes methods and compositions for remodeling a peptide molecule, which includes adding or deleting one or more glycosyl groups to a peptide, and / or adding a modifying group to the peptide.

BR0315178-6A 2002-10-09 2003-10-08 Erythropoietin: remodeling and glycoconjugation of erythropoietin BR0315178A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2002/032263 WO2003031464A2 (en) 2001-10-10 2002-10-09 Remodeling and glycoconjugation of peptides
US10/287,994 US7138371B2 (en) 2001-10-10 2002-11-05 Remodeling and glycoconjugation of peptides
US36077003A 2003-01-06 2003-01-06
US36077903A 2003-02-19 2003-02-19
US10/410,945 US7214660B2 (en) 2001-10-10 2003-04-09 Erythropoietin: remodeling and glycoconjugation of erythropoietin
PCT/US2003/031974 WO2004033651A2 (en) 2002-10-09 2003-10-08 Erythropoietin: remodeling and glycoconjugation of erythropoietin

Publications (1)

Publication Number Publication Date
BR0315178A true BR0315178A (en) 2005-08-16

Family

ID=34841934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315178-6A BR0315178A (en) 2002-10-09 2003-10-08 Erythropoietin: remodeling and glycoconjugation of erythropoietin

Country Status (2)

Country Link
BR (1) BR0315178A (en)
NZ (1) NZ539415A (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20150064246A (en) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 Methods of treatment using glycopegylated g―csf
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
KR101582841B1 (en) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 Conjugated factor viii molecules

Also Published As

Publication number Publication date
NZ539415A (en) 2008-12-24

Similar Documents

Publication Publication Date Title
BR0213207A (en) peptide remodeling and glycoconjugation
MXPA05003730A (en) Erythropoietin: remodeling and glycoconjugation of erythropoietin.
BR0315178A (en) Erythropoietin: remodeling and glycoconjugation of erythropoietin
CY1110602T1 (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF GEL OR SOLUTION BASED ON DIABROSTEOSTERONE, METHODS OF PREPARATION AND USES
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
CY1112781T1 (en) 2'-FLUORO-2'-DEOXYTETRAHYROIDURIDES AS CYTIDINE DISEASE INHIBITORS
BRPI0410630A (en) nk1 antagonist
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
ECSP099027A (en) ANTI-DLL4 ANTIBODIES AND METHODS THAT USE THEM
SE0101675D0 (en) Novel composition
EA200601554A1 (en) SUBSTITUTED INDOL-O-GLUCOSIDES
BRPI0609765A8 (en) isoalkane mixture, method for the preparation thereof, cosmetic or pharmaceutical composition, and use of an isoalkane mixture
CY1112591T1 (en) FROM THE ORAL PHARMACEUTICAL FORMS OF CLANDRIVIN
DE602004027251D1 (en) PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONDERIVATES
BR0003072A (en) Cylinder lock with magnetically operated guidance means
EA200500899A1 (en) ANTAGONISTS OF ADDROSE DIPHOSPHATE PLATELET RECEPTOR
CY1114532T1 (en) (2R) -2 - [(4-SULPHONYL) AMINOFINYL] PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS Containing
BR9909805A (en) Certain endothelin converting enzyme thiol inhibitors
CY1109444T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CYCLICAL SOMATOSTATIN analogues
EA200600590A1 (en) PHARMACEUTICAL COMPOSITIONS OF MODAFINIL WITH MODIFIED DELIVERY
BRPI0516363A (en) hair care composition and process for preparing a hair composition
BR0212902A (en) Shock Resistant Polymer Modified Compositions
BRPI0415450A (en) antibiotic compositions
BR0303912A (en) Makeup for conditioning, makeup for durable conditioning, method for conditioning, method for lasting conditioning, method for care or treatment and kit for care, treatment, conditioning or lasting conditioning
BRPI0405791A (en) Noble metal preparations and gloss preparations for direct and indirect screen printing

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOGENERIX AG (DE)

Free format text: TRANSFERIDO DE: NEOSE TECHNOLOGIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BIOGENERIX AG (DE)

B25D Requested change of name of applicant approved

Owner name: BIOGENERIX GMBH (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.